Materias dentro de su búsqueda.
Mostrando 1 - 20 Resultados de 110,380 Para Buscar '"Lu'an"', tiempo de consulta: 0.79s Limitar resultados
  1. 1
    “…It was tested in selected patients whether the substance is superior to [(177)Lu]Lu-DOTA-TOC. METHODS: Activity kinetics in organs and tumours after [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC were compared intraindividually in five patients with progressive somatostatin receptor-positive disease scheduled for radionuclide therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
  2. 2
    “…RESULTS: The total absorbed dose with uncertainty is presented for 59 treatments with [(177)Lu]Lu-DOTATOC and 56 treatments with [(177)Lu]Lu-DOTATATE. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
  3. 3
    “…The FAPi agents, [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2), were administered in two different groups of patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
  4. 4
    “…MATERIALS AND METHODS: A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [(177)Lu]Lu-PSMA I&T, and a matched cohort of 55 patients treated with [(177)Lu]Lu-PSMA-617. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
  5. 5
    “…For prostate-specific membrane antigen-directed radioligand therapy (PSMA-RLT), [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T are the currently preferred compounds. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
  6. 6
    “…BACKGROUND: Targeted radionuclide therapy with [(177)Lu]Lu-PSMA I&T (zadavotide guraxetan) has proven high efficacy and safety in treating patients with advanced prostate cancer worldwide. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Improved quality control of [(177)Lu]Lu-PSMA I&T
  7. 7
    “…INTRODUCTION: For the implementation of suitable radiation safety measures in [(177)Lu]Lu-PSMA-617 therapy, additional insight into excretion kinetics is important. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
  8. 8
    “…BACKGROUND: Individualized dosimetry is recommended for [(177)Lu]Lu-PSMA radioligand therapy (RLT) which is resource-intensive and protocols are often not optimized. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
  9. 9
    “…CASE PRESENTATION: A case of extravasation of [(177)Lu]Lu-DOTATOC with a treatment strategy involving exercise and elevation of the affected arm and application of a compression bandage and heating is reported. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
  10. 10
    “…Treatment of neuroendocrine tumours with the radiolabelled somatostatin receptor subtype 2 (SST(2)) peptide agonist [(177)Lu]Lu-DOTA-TATE is effective and well-established. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
  11. 11
    Publicado 2020
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lu pour vous
  12. 12
    Publicado 2020
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lu pour vous
  13. 13
    Publicado 2020
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lu pour vous
  14. 14
    “…Single crystals of LuAG:Ce, LuAG:Pr and un-doped LuAG were grown by the vertical Bridgman method and studied for radiation hardness under gamma-rays with doses in the range 10-10(5) Gy (Co-60). …”
    Enlace del recurso
    Enlace del recurso
    Radiation hardness of LuAG:Ce and LuAG:Pr scintillator crystals
  15. 15
    “…Here, we labelled the third-generation human anti-CD20 antibody ofatumumab with (177)Lu, determined the in vitro characteristics of [(177)Lu]Lu-ofatumumab, estimated human dosimetry, and assayed tumor targeting and therapeutic efficacy in a murine model of disseminated NHL. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cure of Disseminated Human Lymphoma with [(177)Lu]Lu-Ofatumumab in a Preclinical Model
  16. 16
    “…BACKGROUND: As for any other nuclear medicine treatment, patients treated with [(177)Lu]Lu-DOTA-TATE should be given some radiation protection recommendations after being discharged to limit the dose received by family members and public. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Individualisation of radiation protection recommendations for patients treated with [(177)Lu]Lu-DOTA-TATE
  17. 17
    “…This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [(177)Lu]Lu-DOTA-TATE to everolimus, sunitinib and best supportive care (BSC) for extending progression-free survival and overall survival in patients with advanced, unresectable gastrointestinal (GI)-NETs and P-NETs. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Matching-adjusted indirect treatment comparison of [(177)Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [(177)Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
  18. 18
    por Lu, Xun, 1881-1936
    Publicado 2003
    Materias: “…371643 Lu, Xun, 1881-1936 Cuentos chinos…”
    Libro
    Selected stories of Lu Hsun /
  19. 19
    Enlace del recurso
    Proton radioactivity of $^{151}$Lu
  20. 20
    Publicado 2020
    “…First Person is a series of interviews with the first authors of a selection of papers published in Biology Open, helping early-career researchers promote themselves alongside their papers. Hao Lu is first author on ‘ Reissner fiber-induced Urotensin signaling from CSF-contacting neurons prevents scoliosis of the vertebrate spine’, published in BiO. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    First person – Hao Lu
Herramientas de búsqueda: RSS